Mesenchymal stem cell-derived conditioned medium demonstrates antifungal activity against ocular isolates of Candida albicans and Aspergillus flavus: a proof-of-concept study
Experimental Eye Research · 2026
DOI: 10.1016/j.exer.2026.111185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2026. Verfasst von Sairam Abbireddy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Prof. Brien Holden Eye Research Centre, Hyderabad Eye Research Foundation, L V Prasad Eye Institute, Hyderabad, 500034, India; Sudhakar and Sreekanth…. Hauptthemen laut MEDLINE: Candida albicans, Mesenchymal Stem Cells, Aspergillus flavus, Antifungal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Hyderabad Eye Research Foundation, Indian Council of Medical Research.
Abstract (Originalsprache)
Ocular fungal infections are potentially sight threatening and their treatment is challenged by increasing burden of antifungal resistance. This study, in search of novel therapeutic strategies, aims to evaluate the antifungal efficacy of mesenchymal stem cell-derived conditioned medium (MSC-CM) derived from human adipose tissue (AD), bone marrow (BM), dental pulp (DP), and umbilical cord (UC) sources against ocular clinical isolates of Candida albicans and Aspergillus flavus. The effect of MSC-CM on fungal growth was evaluated by colony-forming unit assay, whereas morphological alterations were assessed using scanning electron microscopy (SEM). MSC-CM from all four tissue sources significantly inhibited the growth of C. albicans and A. flavus. Compared with control, AD-MSC-CM showed comparatively greater reduction across both the ATCC (36.17 × 109 CFU/mL vs 1.52 × 109 CFU/mL)) and ocular clinical strains (51.30 × 1010 CFU/mL vs 1.07 × 1010 CFU/mL) of C. albicans whereas DP-MSC-CM demonstrated the highest inhibition for A. flavus (ATCC: 17.14 × 1010 CFU/mL vs 2.003 × 1010 CFU/mL, and Clinical: 4.91 × 1012 CFU/mL vs 0.710 × 1012 CFU/mL). SEM imaging confirmed morphological damage, including surface irregularities, invaginations, and cell wall deformations in MSC-CM-treated fungi. These findings, for the first time, present a proof-of-concept that MSC-CM may serve as a promising anti-fungal agent for fungal keratitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prof. Brien Holden Eye Research Centre, Hyderabad Eye Research Foundation, L V Prasad Eye Institute, Hyderabad, 500034, India; Sudhakar and Sreekanth Ravi Stem Cell Biology Laboratory, Centre for Ocular Regeneration, L…
- Prof. Brien Holden Eye Research Centre, Hyderabad Eye Research Foundation, L V Prasad Eye Institute, Hyderabad, 500034, India; Jhaveri Microbiology Centre, L V Prasad Eye Institute, Hyderabad, 500034, India.
- The Ramoji Foundation Centre for Ocular Infections, L V Prasad Eye Institute, Hyderabad, 500034, India; Shantilal Shanghvi Cornea Institute, L V Prasad Eye Institute, Hyderabad, 500034, India.
Förderung
- Hyderabad Eye Research Foundation
- Indian Council of Medical Research
Zitieren
APA
Abbireddy, S., Joseph, J., Bagga, B., & Shukla, S. (2026). Mesenchymal stem cell-derived conditioned medium demonstrates antifungal activity against ocular isolates of Candida albicans and Aspergillus flavus: a proof-of-concept study. Experimental Eye Research. https://doi.org/10.1016/j.exer.2026.111185
Vancouver
Abbireddy S, Joseph J, Bagga B, Shukla S. Mesenchymal stem cell-derived conditioned medium demonstrates antifungal activity against ocular isolates of Candida albicans and Aspergillus flavus: a proof-of-concept study. Experimental Eye Research. 2026. doi:10.1016/j.exer.2026.111185
BibTeX
@article{Abbireddy2026,
author = {Abbireddy, Sairam and Joseph, Joveeta and Bagga, Bhupesh and Shukla, Sachin},
title = {Mesenchymal stem cell-derived conditioned medium demonstrates antifungal activity against ocular isolates of Candida albicans and Aspergillus flavus: a proof-of-concept study},
journal = {Experimental Eye Research},
year = {2026},
doi = {10.1016/j.exer.2026.111185}
}
EUVIMED